Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Richmond, Virginia 23298


Purpose:

The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.


Criteria:

Inclusion Criteria: - Patients with type 1 diabetes mellitus, who have a stable functioning renal transplant, are taking the appropriate maintenance immunosuppression and have no severe health problems that preclude them receiving an islet transplant will be considered for inclusion. Exclusion Criteria: - Have a history of or findings suggestive of unstable diabetic complications (e.g. active eye disease) - Active infections (clinically or by laboratory testing) - History of current malignancy or suspicion of malignancy until properly investigated and excluded - Liver or biliary abnormalities - Unstable cardiovascular disease - Findings to suggest immunological sensitization or those women who have the potential to get pregnant and are not using a sufficient method of contraception


NCT ID:

NCT00784966


Primary Contact:

Principal Investigator
Adrian H Cotterell, M.D.
Virginia Commonwealth University Health System


Backup Contact:

N/A


Location Contact:

Richmond, Virginia 23298
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.